Rebus Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RBSH research report →
About the company
Rebus Holdings, Inc. is dedicated to pioneering highly targeted therapies for oncology. Its flagship investigational product, RT-AR001, operates as an adenosine receptor antagonist.
- CEO
- Raul Silvestre
- IPO
- 2009
- Employees
- 1
- HQ
- Westlake Village, CA, US
Price Chart
- Market Cap
- $3.21K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 19.88%
- ROIC
- 13.48%
- Revenue
- $0 · 0.00%
- Net Income
- $-1,020,000 · -137.81%
- EPS
- $-0.03 · -109.17%
- Op Income
- $-664,000
- FCF YoY
- -1.88%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 10.00
- Avg Volume
- 1.29K
Get TickerSpark's AI analysis on RBSH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RBSH coverage
Recent articles, reports, and earnings notes.
No research on RBSH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RBSH report →Similar companies
Peers in the same neighborhood.